Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma
David S. Lee(Washington University in St. Louis), José P. Zevallos(University of Pittsburgh Medical Center), Cameron C. Wick(Washington University in St. Louis), Dorina Kallogjeri(Washington University in St. Louis), Douglas R. Adkins(Washington University in St. Louis), Cathryn Collopy(Washington University in St. Louis), Wade L. Thorstad(Washington University in St. Louis), Theresa Tharakan(Washington University in St. Louis), Jessica Ley(Washington University in St. Louis), Peter Oppelt(Washington University in St. Louis), Rajwant S. Mahal(Washington University in St. Louis)
Cited by 5
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
|The Lancet Oncology|2013|748
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
|Journal of the National Comprehensive Cancer Network|2022|532